{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02530125: Phase 2 Interventional Terminated Stage III Diffuse Large B-Cell Lymphoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00079495: Phase 2 Interventional Completed Multiple Sclerosis
(2003)
Source URL:
Class:
PROTEIN
Tiplimotide (NBI-5788) is an analog of an immunodominant epitope of myelin basic protein (MBP) for the potential intravenous treatment of multiple sclerosis (MS). NBI-5788-reactive T-cell lines generated from NBI-5788-treated patients exhibited an increased frequency of cross-reactivity with MBP peptide 83-99 compared with NBI-5788-reactive lines from control MS patients. Cytokine secretion by APL-reactive T-cell lines from NBI-5788-treated MS patients was more frequently T-helper 2-like compared with T-cell lines from untreated MS patients. Not every patient exhibited a robust T-cell response to NBI-5788 administration. Tiplimotide had been in phase II clinical trial for the treatment of multiple sclerosis. However, this development was discontinued.
Status:
Investigational
Source:
NCT02265744: Phase 2 Interventional Completed Lupus
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:alicdamotide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
USAN:LIFASTUZUMAB [USAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04182373: Phase 3 Interventional Completed Preeclampsia
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03739606: Phase 2 Interventional Withdrawn Acute Biphenotypic Leukemia
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01307891: Phase 2 Interventional Completed Breast Cancer
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02365662: Phase 1 Interventional Terminated Head and Neck Squamous Cell Carcinoma
(2015)
Source URL:
Class:
PROTEIN
